Freedom Broker downgrades Amgen stock rating on valuation despite raising price target
Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.
How this was made
The 30-second read
Why it matters
Analyst downgrade to Hold may cause short‑term pullback despite higher target; investors will watch upcoming data releases.
Market read
The downgrade provides a fresh catalyst for traders to reassess Amgen's recent rally.
What to watch
Upcoming trial data for IMDELLTRA and long‑term growth from biosimilars may support a higher valuation.
Background
Amgen reported strong Q3 earnings, beating revenue and EPS expectations, and announced positive trial results for a lung‑cancer drug.
Ticker impact
Freedom Broker downgraded Amgen to Hold and raised its price target to $470, citing strong quarterly results and new trial data.
likely modest downside pressure as investors digest the downgrade
The downgrade signals reduced upside expectations even though the target is higher; market may price in a short‑term pullback.
Market effects
May prompt a brief reassessment of healthcare stocks that have recently rallied on earnings beats.
Primarily U.S. market impact; limited effect on other regions.
Low global relevance beyond Amgen and its peers.
Counterpoint
The raised price target suggests upside potential; the downgrade could be an overreaction.
Key entities
- AnalystFreedom Broker
Equity research firm issuing the downgrade and target raise.
- CompanyAmgen
Biopharma firm reporting earnings and trial results.
